Y90-DOTATATE in Gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Survival Following Different Indications for Treatment

#252

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) is an increasingly used treatment for GEP -NETs but there is limited data on indications, efficacy and survival.

Aim(s): To assess indications and survival of patients with GEP-NETs treated with Y90-DOTATATE and to assess the value of post-treatment response.

Materials and methods: Seventy-six patients with metastatic GEP-NETs with either radiological progression (RP), breakthrough symptoms despite treatment, or both, completed three cycles of Y90DOTATATE. Progression-free survival (PFS) and overall survival (OS) were assessed from date of first cycle. Post-treatment response was assessed by CT/MRI(RECIST) 6-12 weeks after the last cycle.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Khan M, El-Khouly F, Quigley A, Caplin M, Toumpanakis C,

Keywords: neuroendocrine tumor, radionuclides, survival, therapy,